A new inter partes review, IPR2026-00400, was filed on June 22, 2026, at the Patent Trial and Appeal Board against Thorne Research, Inc. The proceeding is one to watch for companies operating at the intersection of dietary supplements, formulations, and health-focused consumer products, where patent value often turns on how broadly claims are drafted and how well they withstand validity attacks based on published prior art.
At this stage, the publicly available docket information identifies Thorne Research, Inc. as the patent owner, but practitioners should review the petition and related filings to confirm the specific challenged patent, the real parties in interest, and the exact claims at issue as the record develops. In most PTAB proceedings, those details quickly become central to both the institution decision and any parallel district court or competitive disputes. View full case on Docket Alarm
What makes this filing notable is the likely importance of the grounds for review. As with many IPR petitions involving formulation or composition patents, challengers frequently rely on combinations of printed publications asserting that the claimed invention is anticipated under 35 U.S.C. § 102 or obvious under 35 U.S.C. § 103. For patent owners in the life sciences and wellness sectors, these cases often test whether a claimed composition, dosage, delivery format, or method of use reflects a true inventive step—or an optimization that the PTAB may view as predictable in light of prior art references.
Patent practitioners should follow this case for several reasons. First, it may offer another data point on how the PTAB evaluates patents in the supplement and nutraceutical space, where prior art can include scientific literature, product references, and international publications. Second, if the challenged claims involve ingredient combinations or treatment-related methods, the Board’s treatment of motivation to combine, reasonable expectation of success, and objective indicia could be particularly useful for prosecution and post-grant strategy. Third, for in-house IP counsel, the proceeding may underscore how vulnerable commercially important formulation patents can be if the specification and prosecution history do not clearly support nonobviousness.
As the petition, preliminary response, and any institution decision are filed, this matter should provide a useful window into PTAB scrutiny of health-product patents and the continuing role of IPRs in competitive product markets. For attorneys advising patent owners or challengers, this is the kind of docket that can help sharpen both claim drafting and invalidity strategy.